The market size of Smoking Cessation and Nicotine Addiction is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Embera NeuroTherapeutics, Inc, Axsome Therapeutics, Currax Pharmaceuticals LLC, Omeros Corporation and others…
[Las Vegar, United States] – DelveInsight’s “Smoking Cessation and Nicotine Addiction Market Insights, Epidemiology, and Market Forecast 2034.” The report offers a detailed examination of Smoking Cessation and Nicotine Addiction, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
To Know in detail about the Smoking Cessation and Nicotine Addiction Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Smoking Cessation and Nicotine Addiction Market Forecast
Key Findings from the Smoking Cessation and Nicotine Addiction Market Report:
-
The Smoking Cessation and Nicotine Addiction market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2019-2032).
-
In August, 2024: Rose Research Center, LLC announced that their randomized double-blind placebo-controlled trial (N=180) will evaluate the impact of combining zonisamide and bupropion on the process of switching from combustible cigarettes (CCs) to an e- cigarette.
-
In July,2024: Achieve Life Sciences announced that the purpose of their study is to assess the long-term 3 mg cytisinicline three times daily (TID) exposure for 52 weeks.
-
In March, 2024: Achieve Life Sciences announced that a Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline TID for treatment duration of 42 days/6 weeks as well as repeating that duration for a total of 84 days /12 weeks treatment.
-
As per the assessment of DelveInsight, the total prevalent cases of smoking cessation in the 7MM were 46,814,225 in 2022, out of which the US accounted for 23,145,916 cases. These cases are anticipated to decrease during the forecasted period (2023-2032).
-
Gender-specific prevalent cases of tobacco use were higher in males (around 31,040 thousand cases) as compared to females (around 19,846 thousand) in 2023 in the US.
-
Key Smoking Cessation and Nicotine Addiction Companies are as followed: Achieve Life Sciences, NFL Biosciences SAS, Embera NeuroTherapeutics, Inc, Axsome Therapeutics, Currax Pharmaceuticals LLC, Omeros Corporation, Promentis Pharmaceuticals, Otsuka Pharmaceutical
-
Key Smoking Cessation and Nicotine Addiction Therapies are as follows: CHANTIX/ CHAMTIX (varenicline), ZYBAN (bupropion), Cytisinicline (cytisine), NFL-101, EMB-001, Bupropion, Zonisamide, Placebo
-
Launching multiple stage Smoking Cessation and Nicotine Addiction pipeline products is expected to revolutionize market dynamics, further propelling market growth.
Smoking Cessation and Nicotine Addiction Overview:
Nicotine/tobacco dependence is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated tobacco use and that typically include a strong desire to use tobacco, difficulties in controlling its use, persistence in tobacco use despite harmful consequences, a higher priority given to tobacco use than\ other activities and obligations, increased tolerance and sometimes a physical withdrawal state
Smoking Cessation and Nicotine Addiction Drugs Uptake and Pipeline Development Activities:
The drugs uptake section highlights the adoption rate of newly launched or anticipated drugs during the study period. The report includes an analysis of market uptake by drugs, patient uptake by therapies, and individual drug sales. Additionally, it offers insights into Fabry Disease Pipeline Development Activities, examining therapeutic candidates at different stages and the key companies involved.
Smoking Cessation and Nicotine Addiction Therapies and Key Companies:
-
CHANTIX/ CHAMTIX (varenicline): Pfizer
-
ZYBAN (bupropion): GlaxoSmithKline
-
Cytisinicline (cytisine): Achieve Life Sciences
-
NFL-101: NFL Biosciences SAS
-
EMB-001: Embera NeuroTherapeutics, Inc.
For more information about Smoking Cessation and Nicotine Addiction companies working in the treatment market, visit Smoking Cessation and Nicotine Addiction Clinical Trials
Smoking Cessation and Nicotine Addiction Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Smoking Cessation and Nicotine Addiction.
Smoking Cessation and Nicotine Addiction Epidemiology Segmentation:
The Smoking Cessation and Nicotine Addiction market report provides epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Smoking Cessation and Nicotine Addiction
-
Prevalent Cases of Smoking Cessation and Nicotine Addiction by severity
-
Gender-specific Prevalence of Smoking Cessation and Nicotine Addiction
-
Diagnosed Cases of Episodic and Chronic Smoking Cessation and Nicotine Addiction
Smoking Cessation and Nicotine Addiction Market Drivers and Barriers:
The Smoking Cessation and Nicotine Addiction Market Forecast report highlights key drivers and barriers shaping the Smoking Cessation and Nicotine Addiction market dynamics, providing insights into factors influencing growth and challenges that may be encountered.
Scope of the Smoking Cessation and Nicotine Addiction Market Report:
-
Study Period: 2020-2034
-
Coverage: 7MM (The United States, EU5, and Japan)
-
Key Smoking Cessation and Nicotine Addiction Companies: Achieve Life Sciences, NFL Biosciences SAS, Embera NeuroTherapeutics, Inc, Axsome Therapeutics, Currax Pharmaceuticals LLC, Omeros Corporation, Promentis Pharmaceuticals, Otsuka Pharmaceutical
-
Key Smoking Cessation and Nicotine Addiction Therapies: CHANTIX/ CHAMTIX (varenicline), ZYBAN (bupropion), Cytisinicline (cytisine), NFL-101, EMB-001, Bupropion, Zonisamide, Placebo
-
Smoking Cessation and Nicotine Addiction Therapeutic Assessment: Current marketed and emerging therapies
-
Smoking Cessation and Nicotine Addiction Market Dynamics: Smoking Cessation and Nicotine Addiction Market drivers and Smoking Cessation and Nicotine Addiction barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Smoking Cessation and Nicotine Addiction Unmet Needs: Insights into unmet needs, KOL’s views, Analyst’s views, Market Access, and Reimbursement.
To access the full report and gain a deeper understanding of Smoking Cessation and Nicotine Addiction market outlook, drug uptake, treatment scenario, and epidemiology trends, Smoking Cessation and Nicotine Addiction Market Forecast
About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.
Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432 , Las Vegas
State: Nevada (89107)
Country: United States
Website : https://www.delveinsight.com/consulting